Covid-19: Oxford University vaccine is highly effective

Astra Zenaca. The Muslim Times’ Chief Editor’s comment: I will be concerned about this vaccine until we are shown the resolution of the two cases of transverse myelitis that occurred earlier when the trial was stopped

The Muslim Times’ Editor’s comment: The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines. Suggested reading by the Muslim Times: Covid 19 is Not, Jewish, Christian, Muslim, Hindu or Buddhist

Source: BBC

By James Gallagher

The coronavirus vaccine developed by the University of Oxford is highly effective at stopping people developing Covid-19 symptoms, a large trial shows.

Interim data suggests 70% protection, but the researchers say the figure may be as high as 90% by tweaking the dose.

The results will be seen as a triumph, but come after Pfizer and Moderna vaccines showed 95% protection.

However, the Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two.

So the vaccine will play a significant role in tackling the pandemic, if it is approved for use by regulators.

“The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [the virus],” said the vaccine’s architect, Prof Sarah Gilbert.

The UK government has pre-ordered 100 million doses of the Oxford vaccine and AstraZeneca says it will make three billion doses for the world next year.

Prime Minister Boris Johnson said it was “incredibly exciting news” and that while there were still safety checks to come, “these are fantastic results”.

Read further

2 replies

  1. Drugmaker AstraZeneca announced on Monday that its experimental coronavirus vaccine has shown an average efficacy of 70% in its large scale trials — the latest of several vaccine trials worldwide to post their results this month.

    The vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen, and 62% efficacy in a second regimen. That averages to a 70% efficacy, AstraZeneca said.

    The company said in a news release that its vaccine was “highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.”
    The interim analysis included a total of 131 Covid-19 cases, according to the release.

    Other vaccines in the works: This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against coronavirus, and Pfizer announced its vaccine was 95% effective.

  2. AstraZeneca Plc and the University of Oxford face mounting questions about their Covid-19 vaccine trial results after acknowledging a manufacturing error.

    While an announcement earlier this week by Astra and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the U.K. partners have sparked worries, with some expressing doubts about whether U.S. regulators would clear it.

    Astra and Oxford had said their vaccine was 90% effective when a half-dose was given before a full-dose booster. Two full doses showed an efficacy of 62%. But the head of the U.S. vaccine program known as Operation Warp Speed said the next day that the dose showing the higher level of effectiveness was tested in a younger population.

    In a statement, Oxford said a difference in manufacturing processes led to later phases of the trials having a half-dose given instead of a full one. When it was apparent that a lower dose was used, it was discussed with regulators, and an agreement was reached to push ahead with the two regimens, the statement said.

Leave a Reply